An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade

Pathology Research and Practice

Volumn 208, Issue 4, 2012, Pages 221-224

  Mahzouni, Parvin ^a   Movahedipour, Mohammad ^a  

^a UNIVERSITY OF ISFAHAN   (Iran)

Author keywords

ErbB 2; HER2; Meningioma; Meningioma grading

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; PRIMARY TUMOR; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84859442630     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.01.009     Document Type: Article

References (48)

1. Andersson U., et al. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol. 2004, 108(2):135-142.
2. Babu S., et al. Meningiomas: correlation of Ki67 with histological grade. Neurol. India 2011, 59(2):204-207.
3. Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin. Oncol. 2000, 27(5 Suppl. 9):20-26.
4. Bondy M.L., et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008, 113(7 Suppl.):1953-1968.
5. Botelho C.H., et al. Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq. Neuropsiquiatr. 2006, 64(1):60-66.
6. Bruna J., et al. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 2007, 27(2):114-120.
7. Brunelli M., et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am. J. Clin. Pathol. 2008, 129(6):907-911.
8. Chozick B.S., et al. Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. J. Neurooncol. 1996, 27(2):117-126.
9. Commins D.L., Atkinson R.D., Burnett M.E. Review of meningioma histopathology. Neurosurg. Focus 2007, 23(4):pE3.
10. Das P., et al. Medulloblastomas: a correlative study of MIB-1 proliferation index along with expression of c-Myc, ERBB2, and anti-apoptotic proteins along with histological typing and clinical outcome. Childs Nerv. Syst. 2009, 25(7):825-835.
11. Dhesy-Thind B., et al. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res. Treat. 2008, 109(2):209-229.
12. Dietzmann K., von Bossanyi P. Coexpression of epidermal growth factor receptor protein and c-erbB-2 oncoprotein in human astrocytic tumors. An immunohistochemical study. Zentralbl. Pathol. 1994, 140(4-5):335-341.
13. Durand A., et al. Expression of c-Myc, neurofibromatosis type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin. Neuropathol. 2008, 27(5):334-345.
14. Durand A., et al. WHO grade II and III meningiomas: a study of prognostic factors. J. Neurooncol. 2009, 95(3):367-375.
15. Engelhard H.H., Wolters M., Criswell P.S. Analysis of c-erbB2 protein content of human glioma cells and tumor tissue. J. Neurooncol. 1995, 23(1):31-40.
16. Gilbertson R.J., et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br. J. Cancer 1995, 71(3):473-477.
17. Herms J.W., et al. Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J. Pediatr. Hematol. Oncol. 1997, 19(6):510-515.
18. Jacobs T.W., et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am. J. Clin. Pathol. 2000, 113(2):251-258.
19. Kolla S.B., et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int. Urol. Nephrol. 2008, 40(2):321-327.
20. Kovacs A., Stenman G. HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry. Pathol. Res. Pract. 2010, 206(1):39-42.
21. Laurendeau I., et al. Gene expression profiling of ErbB receptors and ligands in human meningiomas. Cancer Invest. 2009, 27(6):691-698.
22. Lebeau A., et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J. Clin. Oncol. 2001, 19(2):354-363.
23. Liu G., et al. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 2004, 64(14):4980-4986.
24. Livasy C.A., et al. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol. Oncol. 2006, 100(1):101-106.
25. Longstreth W.T., et al. Epidemiology of intracranial meningioma. Cancer 1993, 72(3):639-648.
26. Loussouarn D., et al. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum. Pathol. 2006, 37(4):415-421.
27. Mawrin C., Perry A. Pathological classification and molecular genetics of meningiomas. J. Neurooncol. 2010, 99(3):379-391.
28. Meenakshi A., et al. Immunohistochemical assay (IHC) to study C-erbB-2 status of breast cancer using monoclonal antibody CIBCgp185. Hum. Antibodies 2003, 12(4):123-127.
29. Mineo J.F., et al. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J. Neurooncol. 2007, 85(3):281-287.
30. Moradi A., et al. Pathodiagnostic parameters for meningioma grading. J. Clin. Neurosci. 2008, 15(12):1370-1375.
31. Norden A.D., et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J. Neurooncol. 2010, 96(2):211-217.
32. Osman I., et al. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J. Urol. 2005, 174(6):2174-2177.
33. Ozer O., et al. Her-2/neu gene amplification in paraffin-embedded tissue sections of meningioma patients. Turk. Neurosurg. 2009, 19(2):135-138.
34. Patil S., et al. Malignant meningiomas with epithelial (adenocarcinoma-like) metaplasia: a study of 3 cases. Neurosurgery 2011, 69(4):884-892.
35. Potti A., et al. Role of her-2/neu overexpression and clinical features at presentation as predictive factors in meningiomas. Am. J. Clin. Oncol. 2004, 27(5):452-456.
36. Ridolfi R.L., Jamehdor M.R., Arber J.M. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod. Pathol. 2000, 13(8):866-873.
37. Rogers L., Gilbert M., Vogelbaum M.A. Intracranial meningiomas of atypical (WHO grade II) histology. J. Neurooncol. 2010, 99(3):393-405.
38. Santin A.D., et al. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int. J. Gynaecol. Obstet. 2008, 102(2):128-131.
39. Schlegel J., et al. Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J. Neurooncol. 1994, 22(3):201-207.
40. Szelachowska J., Jelen M., Kornafel J. Prognostic significance of intracellular laminin and Her2/neu overexpression in non-small cell lung cancer. Anticancer Res. 2006, 26(5B):3871-3876.
41. Tambo M., et al. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer. Int. J. Urol. 2009, 16(4):369-374.
42. Torp S.H., et al. C-erbB-2/HER-2 protein in human intracranial tumours. Eur. J. Cancer 1993, 29A(11):1604-1606.
43. Tsiambas E., et al. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP 2006, 7(3):283-294.
44. Vermeij J., et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008, 8:p3.
45. von Randow A.J., Schindler S., Tews D.S. Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas. Pathol. Res. Pract. 2006, 202(5):365-372.
46. Wang C.L., et al. Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study. Zhonghua Bing Li Xue Za Zhi 2010, 39(3):156-160.
47. Wickremesekera A., Hovens C.M., Kaye A.H. Expression of ErbB-1 and 2 in vestibular schwannomas. J. Clin. Neurosci. 2007, 14(12):1199-1206.
48. Wickremesekera A., Hovens C.M., Kaye A.H. Expression of ErbB-1 and ErbB-2 in meningioma. J. Clin. Neurosci. 2010, 17(9):1155-1158.